Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

DFMO IN PHASE I NCI CANCER CHEMOPREVENTION TRIALS

Executive Summary

DFMO IN PHASE I NCI CANCER CHEMOPREVENTION TRIALS are under way at Roswell Park Hospital in Buffalo, N.Y. The National Cancer Institute is sponsoring the study to look at the effect of eflornithine (DFMO) use in "higher than normal risk" patients who still have polyps and are post-resection for breast cancer and other carcinomas. The six-month study is set to include 25 patients; 20 patients are currently receiving the drug. The immediate endpoint of the study is the presence of polymene pools in the red blood cells and their relationship to toxicity. Biochemical changes associated with cancer are known to decrease in pools of polymenes. Marion Merrell Dow is developing the anti-protozoale/anti-prypanosomal agent under the brand name Ornidyl (eflornithine). The company filed an NDA in August 1988 for an orphan indication in the treatment of African sleeping sickness. In addition, the company is reportedly conducting Phase III trials for an orphan indication in the treatment of Pneumocystis carinii pneumonia (PCP) infections related to AIDS. Marion Merrell Dow reportedly is not involved in the Roswell Park chemoprevention work. Roswell Park is planning another NCI-sponsored cancer chemoprevention trial in early 1991 to test N-acetylcysteine . This study looks to measure the ability of the drug to affect intracellular, sulfidial-containing compounds such as plutothyone. The study design will be similar to the DFMO trial, enrolling 20 to 25 patients to receive daily oral administration that will increase in the absence of toxicity.
UsernamePublicRestriction

Register

PS018102

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel